Risk-adapted chemotherapy without procarbazine in treatment of children with Hodgkin lymphoma.

about

Risk-adapted chemotherapy without procarbazine in treatment of children with Hodgkin lymphoma.

Item

http://www.wikidata.org/entity/Q46738596

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Risk-adapted chemotherapy with ...... hildren with Hodgkin lymphoma.

@en

Risk-adapted chemotherapy with ...... hildren with Hodgkin lymphoma.

@nl

type

Item

label

Risk-adapted chemotherapy with ...... hildren with Hodgkin lymphoma.

@en

Risk-adapted chemotherapy with ...... hildren with Hodgkin lymphoma.

@nl

prefLabel

Risk-adapted chemotherapy with ...... hildren with Hodgkin lymphoma.

@en

Risk-adapted chemotherapy with ...... hildren with Hodgkin lymphoma.

@nl

P1476

Risk-adapted chemotherapy with ...... hildren with Hodgkin lymphoma.

@en

P2093

Ci Pan

http://www.w3.org/2001/XMLSchema#string

Feng-Juan Lu

http://www.w3.org/2001/XMLSchema#string

Hui-Liang Xue

http://www.w3.org/2001/XMLSchema#string

Jing Chen

http://www.w3.org/2001/XMLSchema#string

Jing-Yan Tang

http://www.w3.org/2001/XMLSchema#string

Yi-Jin Gao

http://www.w3.org/2001/XMLSchema#string

P2860

Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90

Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy.

Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.

The management of Hodgkin disease in the young child.

Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science.

Time trends and characteristics of childhood cancer among children age 0-14 in Shanghai.

Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook.

Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.

POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology Group.

Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease.

P2888

s12519-012-0390-0

P304

32-35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12519-012-0390-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23275102

http://www.w3.org/2001/XMLSchema#string